Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Abatacept in patients with interstitial lung disease and CVID and related disease
DRKS00008783Phase 2Completed
- Sponsor
- Universitätsklinikum Freiburg
- Start
- May 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abatacept in common variable immunodeficiency (CVID) and interstitial lung disease (ILD), sponsored by Universitätsklinikum Freiburg. Started May 2016; status: completed.
02
Drugs
abatacept
03
Conditions
common variable immunodeficiency (CVID)interstitial lung disease (ILD)
Beyond the preview
Go deeper on DRKS00008783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00008783.